Alexander HR - Search Results

1

Continuous intraoperative external monitoring of perfusate leak using iodine-131 human serum albumin during isolated perfusion of the liver and limbs.

Barker WC, Andrich MP, Alexander HR, Fraker DL. Barker WC, et al. Among authors: alexander hr. Eur J Nucl Med. 1995 Nov;22(11):1242-8. doi: 10.1007/BF00801607. Eur J Nucl Med. 1995. PMID: 8575471

2

Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon gamma, and melphalan.

Thom AK, Alexander HR, Andrich MP, Barker WC, Rosenberg SA, Fraker DL. Thom AK, et al. Among authors: alexander hr. J Clin Oncol. 1995 Jan;13(1):264-73. doi: 10.1200/JCO.1995.13.1.264. J Clin Oncol. 1995. PMID: 7799030 Clinical Trial.

3

The use of tumour necrosis factor (TNF) in isolated perfusion: results and side effects. The NCI results.

Fraker DL, Alexander HR. Fraker DL, et al. Among authors: alexander hr. Melanoma Res. 1994 Mar;4 Suppl 1:27-9. Melanoma Res. 1994. PMID: 8038592 Review.

4

Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study.

Fraker DL, Alexander HR, Andrich M, Rosenberg SA. Fraker DL, et al. Among authors: alexander hr. J Clin Oncol. 1996 Feb;14(2):479-89. doi: 10.1200/JCO.1996.14.2.479. J Clin Oncol. 1996. PMID: 8636761 Clinical Trial.

5

Treatment of peritoneal carcinomatosis by continuous hyperthermic peritoneal perfusion with cisplatin.

Alexander HR, Fraker DL. Alexander HR, et al. Cancer Treat Res. 1996;81:41-50. doi: 10.1007/978-1-4613-1245-1_5. Cancer Treat Res. 1996. PMID: 8834574 Review.

6

Isolated limb perfusion for malignant melanoma.

Alexander HR Jr, Fraker DL, Bartlett DL. Alexander HR Jr, et al. Semin Surg Oncol. 1996 Nov-Dec;12(6):416-28. doi: 10.1002/(SICI)1098-2388(199611/12)12:6<416::AID-SSU7>3.0.CO;2-D. Semin Surg Oncol. 1996. PMID: 8914206 Review.

7

Palliation of regional symptoms of advanced extremity melanoma by isolated limb perfusion with melphalan and high-dose tumor necrosis factor.

Fraker DL, Alexander HR, Andrich M, Rosenberg SA. Fraker DL, et al. Among authors: alexander hr. Cancer J Sci Am. 1995 Jul-Aug;1(2):122-30. Cancer J Sci Am. 1995. PMID: 9166465

8

Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver.

Alexander HR Jr, Bartlett DL, Libutti SK, Fraker DL, Moser T, Rosenberg SA. Alexander HR Jr, et al. J Clin Oncol. 1998 Apr;16(4):1479-89. doi: 10.1200/JCO.1998.16.4.1479. J Clin Oncol. 1998. PMID: 9552055 Clinical Trial.

9

Technique and results of hyperthermic isolated hepatic perfusion with tumor necrosis factor and melphalan for the treatment of unresectable hepatic malignancies.

Libutti SK, Barlett DL, Fraker DL, Alexander HR. Libutti SK, et al. Among authors: alexander hr. J Am Coll Surg. 2000 Nov;191(5):519-30. doi: 10.1016/s1072-7515(00)00733-x. J Am Coll Surg. 2000. PMID: 11085732 Clinical Trial.

10

Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer.

Bartlett DL, Libutti SK, Figg WD, Fraker DL, Alexander HR. Bartlett DL, et al. Among authors: alexander hr. Surgery. 2001 Feb;129(2):176-87. doi: 10.1067/msy.2001.110365. Surgery. 2001. PMID: 11174711 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

308 results

Search Page

Filters